Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $473.00 Price Target at JPMorgan Chase & Co.

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price cut by JPMorgan Chase & Co. from $475.00 to $473.00 in a report published on Monday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Truist Financial began coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a “buy” rating and a $385.00 price objective for the company. Citigroup increased their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. The Goldman Sachs Group increased their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a report on Tuesday, September 16th. Finally, Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $457.08.

Alnylam Pharmaceuticals Trading Up 1.0%

Shares of ALNY opened at $464.95 on Monday. The stock’s 50-day moving average is $452.27 and its two-hundred day moving average is $347.50. The stock has a market cap of $60.95 billion, a PE ratio of -188.24 and a beta of 0.36. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. The company’s revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the transaction, the executive vice president directly owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,144 shares of company stock valued at $44,160,261. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. SVB Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth $27,000. Bessemer Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $30,000. Elevation Point Wealth Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $37,000. Finally, Hilltop National Bank bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $41,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.